Want to see IN:TORNTPHARM full AI Analyst Report?
Top Page
Torrent Pharmaceuticals Ltd
(TORNTPHARM)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹5,493.00
▲(53.49% Upside)
Action:Upgraded
Date:05/24/26
The score is driven primarily by strong financial performance (growth, profitability, and generally solid cash generation) and supportive technical trend/momentum. These positives are tempered by a demanding valuation (high P/E and low yield) and a balance-sheet transparency risk stemming from the sharp FY2026 asset increase.
Positive Factors
Revenue Growth Momentum
Consistent multi-year revenue expansion demonstrates durable demand and successful commercialization across the portfolio. Rising revenues provide scale benefits for sales, manufacturing and R&D, supporting reinvestment and product launches that sustain mid-term growth in branded generics.
Negative Factors
Sharp Asset Increase / Transparency Risk
A very large, single‑year asset increase creates comparability and asset‑quality uncertainty. Such a change can obscure recurring returns, raise questions on accounting or one‑off transactions, and complicate investors' ability to judge sustainable capital efficiency and risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Consistent multi-year revenue expansion demonstrates durable demand and successful commercialization across the portfolio. Rising revenues provide scale benefits for sales, manufacturing and R&D, supporting reinvestment and product launches that sustain mid-term growth in branded generics.
Read all positive factors
Torrent Pharmaceuticals Ltd (TORNTPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.67T
Dividend Yield0.84%
Average Volume (3M)7.49K
Price to Earnings (P/E)77.8
Beta (1Y)0.51
Revenue Growth21.40%
EPS Growth13.19%
CountryIN
Employees18,258
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)63.91
Shares Outstanding338,431,850
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio5.00
Price to Book (P/B)17.02
Price to Sales (P/S)10.22
P/FCF Ratio73.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)70.36
Revenue Forecast (FY)₹194.45B
Torrent Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across k...
How the Company Makes Money
Torrent Pharmaceuticals primarily makes money by selling finished-dosage prescription medicines (formulations), with revenues largely driven by branded generics marketed to physicians and healthcare providers. Key revenue streams typically include...
Torrent Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
72
Positive
Cash Flow
76
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 139.80B | 113.17B | 105.62B | 94.64B | 84.19B |
| Gross Profit | 68.24B | 84.33B | 77.75B | 66.36B | 58.81B |
| EBITDA | 32.57B | 37.19B | 35.00B | 28.81B | 21.41B |
| Net Income | 21.63B | 19.11B | 16.56B | 12.45B | 7.77B |
Balance Sheet | |||||
| Total Assets | 443.12B | 149.90B | 150.61B | 150.12B | 131.00B |
| Cash, Cash Equivalents and Short-Term Investments | 23.70B | 6.91B | 10.04B | 7.23B | 5.83B |
| Total Debt | 150.25B | 32.02B | 40.22B | 53.68B | 40.70B |
| Total Liabilities | 267.27B | 73.99B | 82.04B | 88.14B | 71.47B |
| Stockholders Equity | 83.89B | 75.91B | 68.56B | 61.98B | 59.53B |
Cash Flow | |||||
| Free Cash Flow | 19.55B | 19.74B | 28.33B | 17.94B | 16.00B |
| Operating Cash Flow | 26.32B | 25.85B | 32.66B | 23.68B | 18.03B |
| Investing Cash Flow | -127.49B | -5.40B | -1.68B | -24.15B | -1.97B |
| Financing Cash Flow | 105.78B | -22.98B | -27.80B | 770.00M | -17.81B |
Torrent Pharmaceuticals Ltd Technical Analysis
Positive
3578.85
Price Trends
4517.11
Positive
4370.97
Positive
4053.43
Positive
Market Momentum
133.87
Negative
78.85
Negative
90.53
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TORNTPHARM, the sentiment is Positive. The current price of 3578.85 is below the 20-day moving average (MA) of 4669.64, below the 50-day MA of 4517.11, and below the 200-day MA of 4053.43, indicating a bullish trend. The MACD of 133.87 indicates Negative momentum. The RSI at 78.85 is Negative, neither overbought nor oversold. The STOCH value of 90.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TORNTPHARM.
Torrent Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹4.62T | 40.61 | ― | 0.91% | 11.19% | 5.04% | |
73 Outperform | ₹1.14T | 21.15 | ― | 0.57% | 23.12% | 62.27% | |
71 Outperform | ₹1.67T | 77.82 | ― | 0.84% | 21.40% | 13.19% | |
68 Neutral | ₹1.04T | 54.61 | ― | 0.04% | 16.27% | -6.09% | |
67 Neutral | ₹1.03T | 24.23 | ― | 0.63% | 3.19% | -24.30% | |
64 Neutral | ₹1.13T | 22.63 | ― | 1.19% | 16.81% | 11.37% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,971.25
1,539.64
44.87%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,245.75
-5.17
-0.41%
IN:LUPIN
Lupin Limited
2,469.45
551.62
28.76%
IN:MANKIND
Mankind Pharma Ltd.
2,530.50
-92.02
-3.51%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,940.15
254.70
15.11%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,133.85
176.22
18.40%
Torrent Pharmaceuticals Ltd Corporate Events
Torrent Pharma Completes Amalgamation of J. B. Chemicals and Revises Capital Structure
Jul 8, 2026
Torrent Pharmaceuticals Ltd has completed the amalgamation of J. B. Chemicals Pharmaceuticals Ltd into Torrent Pharma following approval by the National Company Law Tribunal, Ahmedabad Bench. Certified copies of the tribunal’s order and the...
Torrent Pharma Completes Amalgamation of J. B. Chemicals and Updates Capital Structure
Jul 8, 2026
Torrent Pharmaceuticals Ltd has completed the court-approved amalgamation of J. B. Chemicals Pharmaceuticals Ltd, with the scheme becoming effective on July 8, 2026, following filings with the Registrar of Companies in Ahmedabad. As a result, J. ...
Torrent Pharma files assured sustainability report for FY 2025-26
Jun 1, 2026
Torrent Pharmaceuticals has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year, integrating it into the annual report and making it available on its website. The report details the company’s ESG fr...
Torrent Pharma Shareholders Approve Merger with J. B. Chemicals
Apr 28, 2026
Torrent Pharmaceuticals’ equity shareholders have approved, by the requisite majority, a Scheme of Amalgamation under which J. B. Chemicals Pharmaceuticals Ltd will be merged into Torrent Pharmaceuticals along with their respective sharehol...
Torrent Pharma Shareholders Approve Amalgamation with J.B. Chemicals
Apr 28, 2026
Torrent Pharmaceuticals Ltd. has disclosed the voting results of its National Company Law Tribunal-convened meeting of equity shareholders held on April 28, 2026, conducted via video conferencing and other audio-visual means. The meeting was calle...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.